Michael B Atkins

57PUBLICATIONS
264CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (57)

|May 18, 2026
Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti-PD-1 Therapy in Clear Cell Renal Cell Carcinoma: analyses of the HCRN GU16-260 trial.

|Mar 23, 2026
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma, version 3.0.

Rana R McKay, Archana Ajmera, Michael B Atkins

|Jan 30, 2026
Partitioned overall survival: comprehensive analysis of survival states over 4 years in CheckMate 9ER comparing first-line nivolumab plus cabozantinib versus sunitinib in advanced renal cell carcinoma.

Hollis Viray, Charlene M Mantia, Opeyemi A Jegede

|Jan 09, 2026
Effects of Vemurafenib ± Cobimetinib on Intratumoral and Host Immunity in Patients With BRAFV600 Mutant Melanoma: Implications for Combination With Immunotherapy.

Suthee Rapisuwon, Craig L Slingluff, Jennifer A Wargo

|Dec 13, 2025
Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers.

Rana R McKay, Sumanta Pal, Wanling Xie

|Dec 08, 2025
Differentiated Thyroid Cancer Is Associated With Sex-specific Immune Response.

Leila Shobab, Jennifer Simpson, Matthew McCoy

Pageof 10

Frequent Collaborators

11 joint publications

Toni K Choueiri

9 joint publications

Meredith M Regan

8 joint publications

Paolo Antonio Ascierto

8 joint publications

David F McDermott